-
Mashup Score: 2
Program: Oral and Poster Abstracts Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Patrick Hagen, MD, MPH 1 *, Surbhi Sidana, MD 2, Terri L. Parker, MD 3, Brian A. Walker, PhD 4, Vaishali Sanchorawala 5, Jeffrey A. Zonder, MD 6, Taxiarchis Kourelis, MD 7, Anita D’Souza, MD 8,9, Heather J. Landau, MD
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Paper: Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey - 5 hour(s) ago
Program: Oral and Poster Abstracts Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I Hematology Di sease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Lymphoid Malignancies Ghulam Rehman Mohyuddin, MD 1, Rajshekhar Chakraborty, MD 2, Katherine Berger 3 *, Ryan Winborg 4 *, Mason S. Barnes, B.S. 5 *, Jorge Arturo Hurtado Martinez, MD 5 *, Jay R. Hydren, PhD 5, Douglas W Sborov, MD 1, Amandeep Godara 1, Brian
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/b9up9OJ2zT by @ManniMD1 and @HealthTree : “the vast majority of patients choose the less toxic option that offe…
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm @ldandersonjr https://t.co/jfvL4Pi0Dj
-
-
Mashup Score: 24Paper: Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) - 14 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies Hematology Disease Topics & Pathways: Therapy sequence, Treatment Considerations Binod Dhakal, MBBS 1, Othman S Akhtar, MD 1, Andrew J. Cowan, MD 2 *, Shambavi Richard, MD 3, Reed Friend 4 *, Matthew J Rees, MD 5 *, Patrick Costello, MS 6 *, Mariola Vazquez Martinez 7 *, Oren Pasvolsky, MD 8, Charlotte B Wagner,
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
6/ #ASH24 Abstract 931 (Dhakal) bsAbs and CAR-T are friends, not foes! Talquetamab bridging before BCMA CAR-T. @end_myeloma: "Only place where BCMA must precede GPRC5D is dictionary." In real life, tal's one of the best #MMsm bridging tools we have! https://t.co/L5R1ojx6cb https://t.co/8T14dYHd2M https://t.co/alyIbXpNQy
-
-
Mashup Score: 3
Program: Oral and Poster Abstracts Type: Oral Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Susan
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Efficacy & Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted #CARTcell Therapy, in Pts w/ Heavily Pretreated RRMM [Dec 9, 2024] @SusanBal9 et al. #ASH24 Abst 922 https://t.co/Nzd5vgDjn7 #mmsm… https://t.co/sHthZvkGH3
-
-
Mashup Score: 1Paper: Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis - 14 hour(s) ago
Program: Oral and Poster Abstract s Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational Research, Genomics, Immunology, Biological Processes Junia Vieira, MD, PhD 1 *, Alison S Park, BSc 2 *, Edgar Gonzalez-Kozlova, PhD 3 *, David Melnekoff, PhD 1 *, Sherry Bhalla, PhD 4 *, Chaitanya Acharya, PhD 5 *, Mark Hamilton, MD 6, George Mulligan, PhD 6, Immune Atlas Network 7 *, Hearn Jay Cho, MD, PhD 8, Li
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/e545T72QSq By @alagana1 and @theMMRF Immune Atlas : t(11;14) patients have a healthier T cell pool which may ma…
-
-
Mashup Score: 1Paper: Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation - 14 hour(s) ago
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster I Hematology Disease Topics & Pathways: Research, Clinical trials, Translational Research, Clinical Research, Measurable Residual Disease Benjamin A Derman, MD 1, Tadeusz Kubicki 2 *, Jennifer H Cooperrider, MD 1, Anna Pula 2 *, Ken Jiang 2 *, Mariel Coradin 3 *, Ravleen Virdi, MSc 3 *, Fionn McLoughlin, PhD 3 *, Luciano Di Stefano, PhD 4 *, Vincent Bonifay, PhD 5 *, Caroline Rougé Dubroc, PharmD 4 *
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
RT @Taxkourel: https://t.co/AkVUfMKPoD A taste of clonotypic MS (peripheral blood) to identify MRD instead of bone marrow biopsies by @bder…
-
-
Mashup Score: 16Paper: 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 - 14 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies 1 University of Washington Fred Hutchinson Cancer Center, Seattle, WA 2 University of
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
4/ #ASH24 Abstract 81 (Banerjee) [COI: I'm very passionate about this!] Urine-free IMWG response criteria (without 24-hr urines in fridge) worked just fine in @BMTCTN 0702. ⬇️ pt discomfort, ⬇️ #MMsm study deviations. The p-value of pee is minimal! https://t.co/O4oWoHsswO https://t.co/QFS3BIXn8y https://t.co/bqWIIxZj3E
-
-
Mashup Score: 8Paper: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma - 14 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? Hematology Disease Topics & Pathways: Plasma Cell Disorders, Education, Diseases, Lymphoid Malignancies, Human 1 Division of Hematology, Mayo Clinic, Rochester, MN 2 Hôpital Maisonneuve-Rosemont, Université de Montréal, Hematology-Oncology and Cell Therapy University Institute, Montreal, QC, Canada 3
Source: ash.confex.comCategories: General Medicine News, Partners & KOLsTweet-
3/ #ASH24 Abstract 83 (Claveau) Q: Well if MRD-P is PD, what isn’t PD in #MMsm? A: Waiting for a confirmatory set of labs... 98% of the time, single PD timepoint is sufficient. Asking pt to return for extra labs means more #timetoxicity and no benefit. https://t.co/4jlDFONB6U https://t.co/n0pHde7L85 https://t.co/psH4Zc5P3C
-
-
Mashup Score: 12Paper: Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis - 14 hour(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice Hematology Disease Topics & Pathways: Measurable Residual Disease Noemi Puig, PhD 1,2, Cristina Agullo 2 *, Bruno Paiva, PhD 3,4,5,6 *, María T Cedena 7 *, Laura Rosiñol Dachs 8,9,10 *, Teresa Contreras 11 *, Joaquín Martínez-Lopez 12,13 *, Albert Oriol 14,15 *, María-Jesús Blanchard, MD, PhD 16,17 *, Rafael
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Reevaluating the IMWG MM CR Criteria with Mass Spectrometry (MS) -MS surpasses the clinical value of BM PC% and sIFE -Study suggests that BM aspirate is only needed for MRD assessment #mmsm #bmtsm @NoemiPuig2 @mvmateos @BrunoPaiva_UNAV https://t.co/CTUMNyiJtu
-
RT @Taxkourel: https://t.co/czov2fOgdS another shameless plug of intergroup trial (SWOG-led) in progress trying to definitively answer the…